Germline Mutations in Predisposition Genes in Pediatric Cancer.

BACKGROUND The prevalence and spectrum of predisposing mutations among children and adolescents with cancer are largely unknown. Knowledge of such mutations may improve the understanding of tumorigenesis, direct patient care, and enable genetic counseling of patients and families. METHODS In 1120 patients younger than 20 years of age, we sequenced the whole genomes (in 595 patients), whole exomes (in 456), or both (in 69). We analyzed the DNA sequences of 565 genes, including 60 that have been associated with autosomal dominant cancer-predisposition syndromes, for the presence of germline mutations. The pathogenicity of the mutations was determined by a panel of medical experts with the use of cancer-specific and locus-specific genetic databases, the medical literature, computational predictions, and second hits identified in the tumor genome. The same approach was used to analyze data from 966 persons who did not have known cancer in the 1000 Genomes Project, and a similar approach was used to analyze data from an autism study (from 515 persons with autism and 208 persons without autism). RESULTS Mutations that were deemed to be pathogenic or probably pathogenic were identified in 95 patients with cancer (8.5%), as compared with 1.1% of the persons in the 1000 Genomes Project and 0.6% of the participants in the autism study. The most commonly mutated genes in the affected patients were TP53 (in 50 patients), APC (in 6), BRCA2 (in 6), NF1 (in 4), PMS2 (in 4), RB1 (in 3), and RUNX1 (in 3). A total of 18 additional patients had protein-truncating mutations in tumor-suppressor genes. Of the 58 patients with a predisposing mutation and available information on family history, 23 (40%) had a family history of cancer. CONCLUSIONS Germline mutations in cancer-predisposing genes were identified in 8.5% of the children and adolescents with cancer. Family history did not predict the presence of an underlying predisposition syndrome in most patients. (Funded by the American Lebanese Syrian Associated Charities and the National Cancer Institute.).

[1]  C. Mathew,et al.  Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer , 2007, Nature Genetics.

[2]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[3]  Maido Remm,et al.  Enhancements and modifications of primer design program Primer3 , 2007, Bioinform..

[4]  K. McBride,et al.  The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly , 2009, Genetics in Medicine.

[5]  K. Offit,et al.  Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks? , 2008, Journal of oncology practice.

[6]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[7]  Å. Borg,et al.  Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes , 2008, Familial Cancer.

[8]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Spunt,et al.  Ewing sarcoma‐family tumors that arise after treatment of primary childhood cancer , 2006, Cancer.

[10]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[11]  C. Bonaïti‐pellié,et al.  Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families , 2008, Journal of Medical Genetics.

[12]  Baljit Singh,et al.  Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. , 2004, Cancer Genetics and Cytogenetics.

[13]  Amar Gajjar,et al.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.

[14]  K. Nathanson,et al.  Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic , 2006, Cancer biology & therapy.

[15]  M. Greene,et al.  Concise handbook of familial cancer susceptibility syndromes - second edition. , 2008, Journal of the National Cancer Institute. Monographs.

[16]  David A. Williams,et al.  Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy , 2015, Nature Genetics.

[17]  Richard W Tothill,et al.  Next-generation sequencing for cancer diagnostics: a practical perspective. , 2011, The Clinical biochemist. Reviews.

[18]  Sujit Kumar Tripathy,et al.  Ewing’s sarcoma as second malignancy following a short latency in unilateral retinoblastoma , 2011, Journal of Orthopaedics and Traumatology.

[19]  Y. Bombard,et al.  Risks to Relatives in Genomic Research: A Duty to Warn? , 2012, The American journal of bioethics : AJOB.

[20]  Larry N. Singh,et al.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.

[21]  Å. Borg,et al.  Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa , 2001, British Journal of Cancer.

[22]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[23]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[24]  R. Mittal,et al.  Ewing’s Sarcoma as Second Malignant Neoplasm after Retinoblastoma: A Case Report , 2007, Medical Principles and Practice.

[25]  Benjamin J. Raphael,et al.  Integrated Analysis of Germline and Somatic Variants in Ovarian Cancer , 2014, Nature Communications.

[26]  G. Giles,et al.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. , 1999, Cancer research.

[27]  Michael C. Rusch,et al.  CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.

[28]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[29]  Zhongming Zhao,et al.  TSGene: a web resource for tumor suppressor genes , 2012, Nucleic Acids Res..

[30]  M. Tsokos,et al.  Ewing sarcoma and sinonasal neuroectodermal tumors as second malignant tumors after retinoblastoma and other neoplasms. , 2001, Medical and pediatric oncology.

[31]  R. Nagarajan,et al.  Hereditary cancer risk assessment in a pediatric oncology follow‐up clinic , 2012, Pediatric blood & cancer.

[32]  Robert Huether,et al.  The genomic landscape of hypodiploid acute lymphoblastic leukemia , 2013, Nature Genetics.

[33]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[34]  Alan D. D'Andrea.  Fanconi anemia , 2003, Current Biology.

[35]  Martin Kircher,et al.  Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. , 2015, Cancer discovery.

[36]  A. Toland,et al.  Methylation not a frequent “second hit” in tumors with germline BRCA mutations , 2009, Familial Cancer.

[37]  Rohini Rau-Murthy,et al.  A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia , 2013, Nature Genetics.

[38]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[39]  H. Samaratunga,et al.  Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation , 2008, Clinical Cancer Research.

[40]  Heather L. Mulder,et al.  An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. , 2012, Cancer cell.

[41]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.

[42]  L. Cannon-Albright,et al.  Is There a Predisposition Gene for Ewing's Sarcoma? , 2010, Journal of oncology.

[43]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[44]  W. Chung,et al.  High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  E. Boerwinkle,et al.  dbNSFP: A Lightweight Database of Human Nonsynonymous SNPs and Their Functional Predictions , 2011, Human mutation.

[46]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[47]  The "duty to warn" a patient's family members about hereditary disease risks. , 2005, JAMA.

[48]  Yih-Leong Chang,et al.  Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers , 2011, Annals of Surgical Oncology.

[49]  Gayatry Mohapatra,et al.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR , 2005, Nature Genetics.

[50]  Diana Eccles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[51]  Aman N. Patel,et al.  CONSERTING: integrating copy-number analysis with structural-variation detection , 2015, Nature Methods.

[52]  J. Benítez,et al.  Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer , 2002, International journal of cancer.

[53]  Kenneth H. Buetow,et al.  Bioinformatics Applications Note Sequence Analysis Bambino: a Variant Detector and Alignment Viewer for Next-generation Sequencing Data in the Sam/bam Format , 2022 .